INNOVIVA, INC. Proceeds from Issuance of Secured Debt
INNOVIVA, INC. (INVA) reported Proceeds from Issuance of Secured Debt of $0 for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-19.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfSecuredDebt · last filed 2020-02-19
- INNOVIVA, INC. proceeds from issuance of secured debt for the quarter ending 2018-12-31 was $0.00.
- INNOVIVA, INC. proceeds from issuance of secured debt for the quarter ending 2017-12-31 was $0.00.
- INNOVIVA, INC. proceeds from issuance of secured debt for the quarter ending 2016-12-31 was $0.00.
- INNOVIVA, INC. proceeds from issuance of secured debt for fiscal 2019 was $0.00.
- INNOVIVA, INC. proceeds from issuance of secured debt for fiscal 2018 was $0.00, a 100.00% decline from fiscal 2017.
- INNOVIVA, INC. proceeds from issuance of secured debt for fiscal 2017 was $250.00M.
- INNOVIVA, INC. proceeds from issuance of secured debt for fiscal 2016 was $0.00.
| Period end | Proceeds from Issuance of Secured Debt 3 month | Proceeds from Issuance of Secured Debt 9 month | Proceeds from Issuance of Secured Debt 12 month |
|---|---|---|---|
| 2019-12-31 | $0.00 10-K · filed 2020-02-19 | ||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-19 | $0.00 10-K · filed 2020-02-19 | |
| 2018-09-30 | $0.00 10-Q · filed 2018-10-31 | ||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-19 | $250.00M 10-K · filed 2020-02-19 | |
| 2017-09-30 | $250.00M 10-Q · filed 2018-10-31 | ||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-19 | $0.00 10-K · filed 2019-02-19 | |
| 2016-09-30 | $0.00 10-Q · filed 2017-11-03 | ||
| 2015-12-31 | $0.00 10-K · filed 2018-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |